The AKTion in non-canonical insulin signaling.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22395698.
- Also identified by DOI 10.1038/nm.2694 and PMC identifier 3982803.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The kinase AKT has been regarded as an obligate intermediate in the insulin signaling pathway that suppresses glucose production by inhibiting the transcription factor forkhead box O1 (FoxO1) after meals. A new study shows that, without AKT-FoxO1 signaling, insulin still contributes to postprandial responses, revealing an AKT-independent pathway for insulin action that might be exploited to treat metabolic disease (pages 388–395).
Medical subject headings
- Forkhead Transcription Factors
- Insulin
- Liver
- Proto-Oncogene Proteins c-akt